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I. INTRODUCTION
Proponents of expansive federal preemption of state law damages ac-
tions begin their critique of state law with the following: federal regulatory
bodies, not common law juries, have the expertise to decide the correct bal-
ance of risk and benefit that regulated industries should be permitted to
pose to the general public. Once a federal agency has decided through the
appropriate regulatory structure that a certain drug is approved or a certain
product design is permissible, state juries should not be permitted to se-
cond-guess that decision. Federal preemption must operate to defeat the
inconsistent actions of state juries because they have neither the expertise to
understand the complex factors at issue in such a balancing act, nor the abil-
ity to see beyond the individual injured plaintiff, or so the argument goes.1
This argument has been made successfully over the past twenty years
in a wide variety of product liability actions involving drugs and medical
devices.2 The structure and content of the federal preemption doctrine has
* Stites and Harbison Professor of Law, Associate Dean for Academic Affairs, Uni-
versity of Kentucky College of Law. Thanks to Dan Hancock, UK Law Class of 2011, for
his superb research assistance in support of this article and to the University of Kentucky
College of Law summer research grant program for its support. Thanks also to the AALS
Torts and Compensation Systems Section leaders, in particular Prof. Cathy Sharkey, for the
opportunity to participate in this Panel discussion at the 2011 AALS Annual Meeting.
1. See Riegel v. Medtronic, Inc., 552 U.S. 312, 325 (2008) ("A jury, on the other
hand, sees only the cost of a more dangerous design, and is not concerned with its benefits; .
. . ."). See generally, Richard C. Ausness, The Impact of Wyeth v. Levine on FDA Regula-
tion ofPrescription Drugs, 65 FOOD & DRUG L.J. 247, 253-59 (2010) (discussing the pro and
con preemption arguments in the context of prescription drug labeling before Wyeth v. Lev-
ine).
2. Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996); Bucknam v. Plaintiffs Legal Com-
mittee, 531 U.S. 341 (2001); Riegel v. Medtronic, Inc., 552 U.S. 312 (2008); Wyeth, Inc. v.
Levine, 129 S.Ct. 1187 (2010). At the time of the presentation of the AALS panel on the
topic of federal preemption in the vaccine injury context, the Supreme Court had not yet
INDIANA HEALTH LAW REVIEW
changed remarkably in that time period.3 From a time of rare findings of
federal preemption of state damages actionS4 to the now constant drum beat
of the pro-preemption argument in virtually any tort damages action that
involves a regulated entity, particularly in the health care field,5 the ques-
tion of whether common law tort doctrines should continue to play a role in
the regulatory framework is more important than ever-I have elsewhere
articulated a number of reasons why I conclude that it should.' The most
important of these is the need for an alternative, complementary mechanism
to the typically static administrative regulatory framework to encourage the
disclosure of, and promote responses to, constantly evolving risk infor-
mation. The longstanding role of the states in regulating public health and
safety, coupled with the inherent inadequacy of any current federal regula-
tory agency to police fully the acquisition of and proper dissemination of
risk information, supports that conclusion.
The National Childhood Vaccine Injury Act8 ("Vaccine Act"), which
is the subject of these remarks, provides a unique administrative structure to
form the backdrop for this argument. The Vaccine Act established a na-
tional vaccine program "for the development of new vaccines and the im-
provement of existing vaccines and a program to compensate the victims of
vaccine-related injuries and deaths."9 Congress established a "no-fault"
compensation system under which awards "can be made to vaccine-injured
persons quickly, easily, and with certainty and generosity."'o The Compen-
sation Program ("Program") is the first step for those who suffer vaccine-
related injuries because the Vaccine Act also permits some claims that do
decided the preemption case involving the National Childhood Vaccine Injury Act of 1986.
Bruesewitz v. Wyeth LLC, 131 S. Ct. 1068 (2011). The Court decided the case on February
28, 2011 in favor of preemption. Id.
3. For explanations of the changes in preemption doctrine over the past decades, see
generally Mary J. Davis, The "New" Presumption Against Preemption, 61 HASTINGS L. J.
1217 (2010); Catherine M. Sharkey, Products Liability Preemption: An Institutional Ap-
proach, 76 GEO. WASH. L. REv. 449 (2008); Mary J. Davis, Unmasking the Presumption in
Favor ofPreemption, 53 S.C. L. REv. 967 (2002).
4. See, e.g., Abbott v. American Cyanamid Co., 844 F.2d 1108 (4th Cir. 1988) (DTP
vaccine); MacDonald v. Ortho Pharm. Corp., 475 N.E.2d 65 (Mass. 1985) (birth control
pills). See also DAVID G. OWEN, PRODUCTS LIABILITY 909 (2d ed. 2010).
5. See OWEN, supra note 4.
6. Mary J. Davis, The Battle Over Implied Preemption: Products Liability and the
FDA, 48 B.C. L. REv. 1089, 1148-51 (2008). See also Mary J. Davis, On Restating Products
Liability Preemption, 74 BROOK. L. REV. 759, 776-79 (2009).
7. For others who arrive at a similar conclusion, see Elizabeth Cabraser, Due Process
Preempted: Stealth Preemption as a Consequence of Agency Capture, 65 N.Y.U. ANN.
SURV. OF AM. L. 449 (2009).
8. National Childhood Vaccine Injury Act, Pub. L. No. 99-660, 100 Stat. 3743, 3756-
84 (codified at 42 U.S.C. §§ 300aa-1 to 300aa-34) (1987). See generally Lainie Rutkow, et
al., Balancing Consumer and Industry Interests in Public Health: The National Vaccine
Injury Compensation Program and Its Influence During the Last Two Decades, 111 PENN
ST. L. REv. 681 (2007).
9. H.R. REP. No. 99-908 at 1 (1986), reprinted in 1986 U.S.C.C.A.N. 6344, 6344.
10. Id.
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not lead to Program compensation to proceed in the traditional way-a civil
action for damages "just as he or she may have done prior to the enactment
of the legislation."" Congress expressly preempted some tort claims in the
Vaccine Act.12 The question is: which ones? And, more importantly,
should such a legislative directive be expected to respond to the natural evo-
lution of scientific understanding of the regulated risk, and, if so, how?
Current express preemption doctrine, which requires an assessment of con-
gressional intent as the "ultimate touchstone of preemption analysis,"" has
not fully explored that question. One component of preemption analysis,
the "presumption against preemption," which has fallen into disfavor at the
Supreme Court,14 seems to accommodate the need to consider changes in
scientific understanding of risk. When the presumption against preemption
is properly understood, it requires an understanding of the tort system as
uniquely equipped to respond to the uncertainty inherent in the understand-
ing of risk.
One way to frame this important question was articulated recently by
Judge Guido Calabresi of the Unites States Court of Appeals for the Second
Circuit, a long-time prominent tort law scholar.15 In his opening remarks
for a symposium titled "Tort Law in the Shadow of Agency Preemption,"
Judge Calabresi articulated the core issues tort law faces in a world increas-
ingly dominated by administrative regulatory action: (1) "Does national
centralized decision-making, as between safety and accidents-and as to
who bears the cost of safety or the cost of accidents-work better than lo-
cal, diverse, and diffuse decision-making?;" 6 (2) "What are the benefits of
allowing different local decisions? How often in America do we have and
want to have different values, different notions of what life is worth, of
what things are worth?;" 7 and (3) "What does the difference between local-
ized and centralized decision-making tell us about who bears the burden of
these decisions?" 8 This article provides a small contribution to these much
larger questions by asking how courts should respond to the evolution of
scientific understanding of risk in determining who bears the cost of that
risk when assessing congressional intent to preempt traditional state com-
11. Id. Several new substantive and procedural requirements were established for the
recovery of these damages. Id.
12. 42 U.S.C. § 300 aa-22 (1987). This provision's scope has been in issue in recent
litigation. The Supreme Court decided that the provision preempted all design defect litiga-
tion in Bruesewitz v. Wyeth LLC, 131 S. Ct. 1068 (2011). For a fuller discussion of
Bruesewitz, see supra notes and accompanying text.
13. White Motor Co. v. Malone, 435 U.S. 497, 504 (1978).
14. See Davis, The "New" Presumption, supra note 3, at 1220.
15. Hon. Guido Calabresi, Keynote Address at the New York Univ. Annual Survey of
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mon law.
First, this article provides a brief recap of the state of current preemp-
tion doctrine and how it governs the interaction of federal regulation of
product manufacturers and state tort actions related to the actions of those
manufacturers. Second, the article provides observations on how that doc-
trine might apply to vaccine injury litigation. Bruesewitz v. Wyeth, Inc.19
involves the preemptive scope of the Vaccine Act and the unique compen-
sation system Congress created to respond to vaccine injuries. Bruesewitz
was decided on February 22, 2011, and held that design defect claims are
expressly preempted by the Vaccine Act.20 This article endeavors to ex-
plain Bruesewitz in the context of express preemption doctrine generally.
This article also provides observations on the continuing value of state tort
law in the assessment of unreasonable risk. Finally, comments in response
to Judge Calabresi's framing question, asking how to address the uncertain-
ty inherent in acquisition of risk information, will build on the preemption
analysis from Bruesewitz to encourage a narrow application of the scope of
preemption doctrine particularly in the case of pharmaceuticals and medical
devices.
II. MODERN PREEMPTION FRAMEWORK
Preemption doctrine requires, under the Supremacy Clause, that courts
search for congressional intent to preempt as the ultimate touchstone of
preemption analysis.21 Express preemption provisions are to be mined for
their meaning and scope and in the absence of such a provision, limited
doctrines of implied preemption act as gap-fillers where Congress's intent
22
can be presumed based on an actual conflict with state law.
The presumption against preemption is one feature of preemption
analysis that requires a nuanced understanding. Historically, the presump-
tion requires the conclusion that, absent clear and manifest congressional
intent to the contrary, state common law tort actions-as a reflection of the
historic police powers of the states-are not preempted by federal regulato-
23
ry action. Congress must be presumed not to displace such actions out of
respect for the concurrent, traditional operation of state police powers. This
presumption has been described as a fundamental reflection of federalism
principles that prevents preemption analysis from becoming a tool of the
f9. Bruesewitz v. Wyeth, Inc., 561 F.3d 233 (3d Cir. 2009), affd, 131 S. Ct. 1068
(2011).
20. Id.
21. U.S. CONST. art. VI, cl. 2; Retail Clerks Int'l Ass'n, Local 1625 v. Schermerhorn,
375 U.S. 96, 103 (1963).
22. See Davis, The "New" Presumption, supra note 3, at 1221.
23. See Wyeth v. Levine, 129 S. Ct. 1187, 1194 (2009). See also Davis, The "New"
Presumption, supra note 3.
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courts or agencies-any branch other than Congress-to assess preemptive
scope in some freewheeling fashion to displace otherwise applicable state
law, regardless of the perceived value or popularity of that law.24
The Supreme Court's preemption decisions in the last twenty years
have introduced substantial confusion regarding the preemption framework
generally and the application of the presumption against preemption specif-
ically. As a result, it seems that there is a tendency for courts to view the
topic of preemption very narrowly and to lose many of the nuances that are
involved, but that is the world in which courts operate. Courts are looking
for a model, a rational framework by which to answer these intractable
questions surrounding the concurrent application of state law in an increas-
ingly federalized world of tort duties and obligations. So when the Su-
25preme Court decides a case like Cipollone v. The Liggett Group, Inc.,
which found preemption of some common law tort claims based on the fed-
eral cigarette labeling laws prohibition of conflicting state law "require-
ments,"2 6 lower courts, based on expansive pro-preemption arguments of
product manufacturers, tended to find other legislative enactments that re-
ferred to "requirements" as broadly preemptive in scope.2 7 Cipollone actu-
ally articulated a narrow construction of express preemption provisions in
light of the presumption against preemption, but the justices disagreed
strongly on the nature of that analysis. 28 I continue to think that Cipollone's
determination that "requirements" include common law damages actions in
the cigarette labeling statute was misguided. That genie is out of the bottle,
however, and the Court has continued to hold that the use of the word "re-
quirements" may indicate congressional intent to defeat common law dam-
ages actions.29 The ensuing turmoil over how to determine the scope of
express preemption provisions has led to a hodge-podge of confusing,
sometimes conflicting, preemption decisions.
The Court's next preemption opinion, Medtronic, Inc. v. Lohr, also
focused on express preemption, this time under the Medical Device
Amendments ("MDA") to the Food, Drug and Cosmetic Act ("FDCA"),
24. See, e.g., Wyeth, 129 S. Ct. at 1205 (Justice Thomas, concurring, criticizing free-
wheeling judicial assessment under implied obstacle preemption); see also Brief for Kenneth
Starr and Erwin Chemerinsky as Amici Curiae Supporting Petitioner, Bruesewitz v. Wyeth,
131 S.Ct. 1068 (2011) (No. 09-142).
25. Cipollone v. The Liggett Group, Inc., 505 U.S. 504 (1992).
26. Id. at 515-20.
27. See Medtronic, Inc. v. Lohr, 518 U.S. 470, 483-87 (1996) (discussing the treatment
by courts of the term "requirements" in the MDA to the FDCA, and concluding nothing in
the legislation or its history suggested that common law damages actions were intended to be
requirements).
28. Cipollone, 505 U.S. at 518.
29. Riegel v. Medtronic, Inc., 552 U.S. 312, 325 (2008). See also Robert Rabin, Terri-
torial Claims in the domain of Accidental Harm: Conflicting Conceptions of Tort Preemp-
tion, 74 BROOK. L. REv. 987, 991-994 (2009) (discussing tort duties as "requirements").
30. Lohr, 518 U.S. 470 (1996).
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which preempted state law "requirements." Plaintiff alleged common law
product defect claims arising out of his use of defendant's pacemaker,
which had been approved under the FDA's pre-market notification approval
regulations, a grandfathering method of approval without the heightened
rigor of the more elaborate pre-market approval process. The Court was
divided on whether the MDA preempted the plaintiffs' claims, but all jus-
tices again agreed that the express preemption provision controlled the
analysis.32 The majority opinion applied the presumption against preemp-
tion and, in doing so, concluded that common law damages actions alleging
design defects did not impose "requirements" in this context.33 Four justic-
es concluded that nothing in the legislation, its history, or its basic purpose
suggested that common law damages actions were intended to be require-
ments.34
Importantly, a majority of justices concluded in Lohr that, while gen-
eral common law obligations were not a threat to the non-device specific
federal requirements at issue, 35 where the federal government had weighed
the competing interests relevant to the particular requirement in question,
reached an unambiguous conclusion about how those competing considera-
tions should be resolved in a particular case or set of cases, and implement-
ed that conclusion via a specific mandate on manufacturers or products, an
entirely different case would exist for preemption under the statute and im-
plementing regulations.36 The search for specific federal government
"weighing of competing interests" in subsequent regulatory situations be-
comes a recurring theme in assessing preemption, both express and im-
plied.37
31. Id. at 476-81.
32. Id. at 484-85; id. at 503 (Breyer, J., concurring); id. at 509 (O'Connor, J., concur-
ring and dissenting).
33. Id. at 476-81. Justice Stevens wrote: "[W]e used a presumption against the pre-
emption of state police power regulations to support a narrow interpretation of such an ex-
press command in Cipollone. That approach is consistent with both federalism concerns and
the historic primacy of state regulation of matters of health and safety." Id. at 485.
34. Id. at 487.
35. Id. at 501-02.
36. Id. at 501. Justice Breyer's concurring opinion gave the Court its judgment in the
case, and he interpreted the word "requirement" to include common law damages actions in
some circumstances, but not in this case. Id. at 503-05.
37. Id. The Court also addressed the FDA's preemption position articulated in a for-
mally adopted regulation that implemented its statutory preemption authority. Id. at 497-98.
See also 21 C.F.R. § 808.1 (d)(2) (2008) (no preemption of state or local requirements that
are "equal to, or substantially identical to, requirements imposed"); 21 C.F.R. § 808.1 (d)(1)
(no preemption of "state or local requirements of general applicability"). Federal agency
action regarding preemption may inform preemptive scope if Congress has delegated to the
agency that authority. The Justices disagreed on the extent to which they should rely on an
agency's position on preemption, though in earlier cases the Court had noted that agency
regulations could be informative on defining the scope of preemption where consistent with
statutory language. See CSX Transp. Inc. v. Easterwood, 507 U.S. 658, 670 (1993); Norfolk
& Southern Ry. v. Shanklin, 529 U.S. 344 (2000) (preemption under Federal Railroad Safety
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A few years after Lohr, the Court decided the effect of an express
preemption provision in the National Traffic and Motor Vehicle Safety
("NTMVSA") in Geier v. American Honda Motor Corp.38 The case, in-
volved an allegedly defective automobile that did not have a driver's side
airbag even though the Federal Motor Vehicle Safety Standard 208 permit-
ted manufacturers at the time to choose whether to incorporate such safety
systems.39 Geier, which found implied but not express preemption even
though the statute contained an express preemption provision, is a water-
shed case in the Court's preemption opinions because of its expansive im-
plied preemption analysis. It reflects the power of federal administrative
agency position regarding preemption if that position is based on an as-
sessment of whether an actual conflict would "take from those who would
enforce a federal law the very ability to achieve the law's congressionally
mandated objectives that the constitution, through the operation of ordinary
preemption principles, seeks to protect."40 The Court was persuaded in
Geier to apply implied conflict preemption principles out of concern for the
"careful regulatory scheme" established by NTMVSA, despite the arguably
plain meaning of the savings clause.
The Court's treatment of common law damages actions in Geier illus-
trates the Court's uncertainty about the value of traditional state law's regu-
latory value, even in cases where preemption is being implied. The Geier
Court perceived that common law tort actions might be detrimental to
thoughtfully established federal goals,41 even in the face of congressional
intent to the contrary as evidenced by the savings clause. The Court
weighed the perceived federal regulatory objectives against the general in-
terest the states have in promoting health and welfare and compensating
citizens for injuries suffered by defective products.42 It was somewhat
sympathetic to state concerns of compensating victims and enhancing prod-
uct safety, but concluded that jury-assessed standards would lead to unpre-
dictability and uncertainty in the standard of care.43 The Court did not
mention the presumption against preemption.44 The Geier analysis, which
broadly assessed federal objectives under implied preemption analysis, has
Act, relevance of agency position debated).
38. Geier v. American Honda Motor Corp., 529 U.S. 861 (2000). Geier is a five-to-
four opinion; Justice Breyer writing for the majority, joined by Chief Justice Rehnquist,
Justices O'Connor, Scalia, and Kennedy. Justice Stevens, the author of both the Cipollone
and Medtronic plurality opinions, dissented in an opinion in which Justices Souter, Thomas,
and Ginsberg joined.
39. Id. at 865. The National Traffic and Motor Vehicle Safety Act of 1966, Pub. L.
No. 89-563, 80 Stat. 718 (codified as amended at 49 U.S.C. 30101-30169).
40. Geier, 529 U.S. at 872.
41. Id. at 881. See also Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996).
42. Geier, 529 U.S. at 882-83.
43. Id. at 871.
44. Id. at 894 (Stevens, J. dissenting).
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been criticized for its potential to encourage judicial over-reaching of state
law prerogatives.45
. The Court has also relied variously on the federal government's posi-
tion on preemption, either through agency action or government litigating
position, to establish intent to preempt. Lohr involved a specific agency
rule promulgated to define the scope of the MDA preemption provision pri-
or to litigation and the Court was "substantially informed" by it.46 The
government's position in Geier was found in a wide-ranging assessment of
the history of the regulation and the current Secretary's position in the liti-
gation as well as predecessor Secretary's opinions.47 In the eight years be-
tween Cipollone and Geier, the Court contracted the operation of traditional
state tort laws substantially and therefore increased the likelihood that pro-
preemption arguments would be made based on federal regulatory action.
The Court also resisted discussing the presumption against preemption and
increasingly relied on agency assessments of the role of state tort law as
complementary to federal regulatory action.4 8
Subsequent cases display the Court's own unease in assessing the
scope of express preemption provisions. In Bates v. Dow Agrosciences
LLC,49 the Court spoke openly about the delicate balance that must be
achieved in determining the scope of express preemption provisions, and
about the effect of shifting agency position on that analysis. Bates involved
preemption under the Federal Fungicide, Insecticide and Rodenticide Act
("FIFRA") and failure to warn claims regarding pesticides whose labels
45. Indeed, the Court recently decided a second NTMVSA case involving Standard
208 and found that the regulatory history did not impliedly preempt a common law damages
claim involving rear lap seat belts. Williamson v. Mazda Motor of Am., Inc., 131 S. Ct.
1131 (2011). In Williamson, the Court speaking through Justice Breyer who authored Geier,
concluded that state tort law did not actually conflict with the then current version of Stand-
ard 208 because there was no indication that the federal agency intended to prevent States
from "supplement[ing] through state tort law" federal minimum standards. Id. at 1139. See
also, id. at 1140 (Sotomayor, J., concurring) ("I write separately only to emphasize the
Court's rejection of an overreading of Geier that has developed since that opinion was is-
sued.").
46. Medtronic, Inc. v. Lohr, 518 U.S. 470, 495-96 (1996). Justice Breyer concurred,
agreeing that "the relevant administrative agency possesse[d] a degree of leeway to deter-
mine which rules, regulations, or other administrative actions will have pre-emptive effect."
Id. at 505-06 (Breyer, J., concurring).
47. Geier, 529 U.S. at 883.
48. An example is Sprietsma v. Mercury Marine involving Coast Guard action under
the Federal Boat Safety Act. 537 U.S. 51, 59-60 (2002) (applying 46 U.S.C. §§ 4301-11
(2000)). The Court was faced with whether a Coast Guard decision not to regulate the design
of propeller guards preempted common law claims based on a failure to equip with propeller
guards, and found neither express nor implied conflict preemption. Id. at 64-66. The Court
was influenced by Coast Guard regulations, which preserved state authority in the absence of
federal action, and the Coast Guard consistently concluded that its regulations did not have
preemptive effect, though it had no formal rule on the subject. Id. at 66.
49. 544 U.S. 431 (2005). Bates involved application of the express preemption provi-
sion of the Federal Insecticide, Fungicide, and Rodenticide Act, Pub. L. No. 80-103, 61 Stat.
163 (1947) (codified at 7 U.S.C. §H 134-36).
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were EPA.50 The Court reiterated, however, its adherence to the presump-
tion against preemption because tort litigation "provide[s] an incentive to
manufacturers to use the utmost care in the business of distributing inher-
ently dangerous items."5 1  The Court narrowly analyzed the express
preemption provision, as it had done in Cipollone, specifically rejecting the
conclusion that common law jury verdicts are the equivalent of "require-
ments" simply because they may influence decision-making. 52 The Court
also expressed a sense of frustration at the way the lower courts had read
the term "requirements" broadly after Cipollone, and chastised the "too
quick conclusion" 53 that tort claims were always preempted under statutes
that used that term. The Court concluded that the express preemption pro-
vision preempted very few claims,54 stating, "if Congress had intended to
[prevent the operation] of a long available form of compensation, it surely
would have expressed that intent more clearly."55 The Court endorsed the
parallel operation of common law tort claims, stating they "would seem to
aid, rather than hinder, the functioning of FIFRA . .. [which] contemplates
that pesticide labels will evolve over time, as manufacturers gain more in-
formation about their products' performance in diverse settings ... [T]ort
suits can serve as a catalyst in this process." 56
Three years later, the Court returned to express preemption under the
FDCA MDA. Riegel v. Medtronic, Inc.57 involved allegations of design
defect in devices approved through the pre-market approval process.5 8 The
Court was quite critical of the role of common law tort claims in regulating
product safety, unlike its position in Bates, and was quite expansive in its
50. Bates, 544 U.S. 431.
51. Id. at 449; see also id. at 459 (Thomas, J., concurring in part and dissenting in part)
("Today's decision thus comports with this Court's increasing reluctance to expand federal
statutes beyond their terms through doctrines of implied preemption. This reluctance reflects
that preemption analysis is not [a] freewheeling judicial inquiry into whether a state statute is
in tension with federal objectives, . .. but an inquiry into whether the ordinary meanings of
state and federal law conflict." (citations omitted)).
52. Id. at 445 (reasoning that "[a] requirement is a rule of law that must be obeyed[,
whereas] an event, such as a jury verdict, that merely motivates an optional decision is not a
requirement").
53. Id. at 446.
54. Id. at 451-52.
55. Id.
56. Id. (stating that the Defendant and EPA's concern that "tort suits led to a 'crazy-
quilt' of FIFRA standards or otherwise created [a] real hardship for manufacturers" was
unpersuasive because, as the Court observed, "for much of this period EPA appears to have
welcomed these tort suits.").
57. Riegel v. Medtronic, Inc., 128 S. Ct. 999 (2008).
58. Id. The second MDA preemption case was Bucknam Co. v. Plaintifs' Legal
Committee involving a so-called fraud-on-the-agency theory that the Court found was not
expressly preempted by the MDA's express preemption provision but was impliedly
preempted because policing fraud on an agency is a uniquely federal matter. 531 U.S. 341
(2001).
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description of the scope of express preemption.59  The Court, speaking
through Justice Scalia, seemed less interested in assessing congressional
intent to preempt, which it had done in two prior cases, than in re-affirming
its own understanding of the statute's term "requirements."60  The Court
declared that "requirements" includes common law tort claims, stating:
"Congress is entitled to know what meaning this Court will assign to terms
regularly used in its enactments. Absent other indication, reference to a
State's 'requirements' includes its common-law duties."6 1 This conclusion,
which seems contrary to Bates' analysis and sentiment, is the kind of incon-
sistency that makes express preemption analysis so fraught with uncertain-
ty.
While thus defining the term "requirement" for future congresses, the
Court reiterated its pre-Bates distrust over the operation of common law tort
actions. Justice Stevens, the originator of modem preemption analysis in
Cipollone, had come to speak positively about the general value of state tort
law as a complement to federal regulation, as indicated by his opinion in
Bates. Justice Scalia, the author of Riegel, on the other hand, finds tort law
as applied by juries to be "less deserving of preservation" than other state
regulations. His stated rationale is that juries are incapable of balancing
costs and benefits adequately as they "see[] only the costs of a more dan-
gerous design, and [are] not concerned with [the] benefits" consumers reap
by the manufacturer's design choices.62 The Riegel Court found it "implau-
sible" that Congress would create the "perverse distinction" that grants
greater power to a single state jury than to state officials.63 There is no
mention of the "presumption against preemption." There is certainly little
regard in these remarks for tort law's historic place in contributing to public
safety or for its "catalyzing" effect to increase access to risk information as
discussed in Bates.6
The final pre-Bruesewitz express preemption case meriting discussion
is Altria Group, Inc. v. Good,6 5 decided after Riegel, which involved the
59. 128 S.Ct. 999, 1007.
60. Id.
61. Id. For a different assessment of Congress's intent, see 128 S.Ct. 999, 1013
(Ginsburg, J., dissenting). Justice Stevens, the author of Cipollone, Lohr, Sprietsma, and
Bates, concurred on the scope of "requirements" because he considered it consistent with the
result in Medironic, Inc. v. Lohr, 518 U.S. 470 (1996). 128 S. Ct. 999, 1011-13 (Stevens, J.,
concurring in part and dissenting in part).
62. Id. at 1007.
6 3. Id.
64. Some observers have described Riegel as a fairly narrow application of the MDA
express preemption provision and a logical extension of Medtronic, Inc. v. Lohr, 518 U.S.
470 (1996). See Catherine M. Sharkey, Colloquy, What Riegel Portends for FDA Preemp-
tion of State Law Products Liability Claims, 102 Nw. U. L. REv. 415 nn. 3-4 (2008). See
contra Davis, On Restating Products Liability Preemption, supra note 6 (discussing the im-
portance of the debate in Riegel to the larger discussion of the continuing value of tort law).
65. 129 S.Ct. 538 (2008).
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continuing validity of Cipollone in defining the claims that survived express
preemption under the cigarette labeling laws.66 After Riegel and its eight-
to-one opinion in favor (in dicta, at least) of a more expansive reading of
express preemption provisions, one would have expected that Justice Ste-
vens' plurality opinion in Cipollone had been outgrown. On the contrary,
the Court held that the Cipollone plurality controls the express preemption
analysis of the statute.67 The majority, authored by Justice Stevens, reject-
ed the broader scope of preemption analysis proposed by Justice Scalia in
Cipollone, and advocated in Altria Group by Justice Thomas for the dis-
sent, stating, "Justice Scalia's approach was rejected by seven Members of
the Court, and in the almost 17 years since Cipollone was decided Congress
has done nothing to indicate its approval of that approach." 69 Justice Ste-
vens' opinion confirmed the validity of the presumption against preemption
in conjunction with a fair but narrow reading of the scope of express
preemption.7 0
Bates, Riegel, and Altria Group, as the most recent express preemp-
tion opinions until Bruesewitz, give contrary signals about the role of the
presumption against preemption and determining the scope of congressional
intent to preempt as found in express provisions. Justice Stevens retired in
2010. A different majority may be about to emerge on the scope of
preemption of traditional state tort laws. The Bruesewitz contribution to
express preemption analysis is found in Part III.
III. A FEW LESSONS FROM IMPLIED PREEMPTION AND WYETH V. LEVINE
While implied preemption doctrine is not applicable to Vaccine Act
preemption, the Court's opinion in 2009 in Wyeth v. Levine, 7 which in-
volved the application of implied preemption under the FDCA to pharma-
ceutical labeling claims, is an important contribution to the continuing
debate over the value of state tort law in the regulatory framework for
pharmaceuticals. The Court had not decided an FDCA implied preemption
case since Hillsborough County v. Automated Medical Laboratories, Inc.72
in 1985. In addition, the FDA which had for years been in favor of the con-
current operation of state common law damages actions had changed its
66. Id. at 541-42.
67. Id. at 549 ("In sum, we conclude now, as the plurality did in Cipollone, that 'the
phrase "based on smoking and health" fairly but narrowly construed does not encompass the
more general duty not to make fraudulent statements."' (quoting Cipollone v. Liggett Group,
505 U.S. 504, 529 (1992)).
68. Id. at 545 n.7; see id. at 552-54 (Thomas, J., dissenting).
69. Id. at 545 n.7 (majority opinion).
70. See id. at 543.
71. Wyeth v. Levine, 129 S. Ct. 1187 (2009).
72. Hillsborough County v. Automated Medical Laboratories, Inc., 471 U.S. 707
(1985).
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position on preemption, first in a series of amicus briefs in cases beginning
in 2004 and then in a now discredited 2006 Preamble to new pharmaceuti-
cal labeling regulations. 73 A number of issues had confounded the lower
courts, which needed guidance on the modem state of implied preemption
analysis.74
Levine involved the anti-nausea drug Phenergan that had been ap-
proved in 1955. 75 Plaintiff lost her arm as a result of inadvertent injection
of the migraine drug into an artery, which resulted in gangrene, a risk of
which W eth was aware and which had been warned about in the product's
labeling. Ms. Levine claimed that the labeling inadequately warned of the
risk of gangrene, and the jury agreed.7 7 The Vermont Supreme Court af-
firmed a lower court ruling that Ms. Levine's claims were not impliedly
preempted by the FDA's labeling approvals.7 8
Wyeth made two separate implied conflict preemption arguments:
first that it would have been impossible for it to comply with the state law
duty to warn without violating federal law, and, second, that recognition of
the plaintiffs claims would act as an obstacle to the accomplishment of
federal objectives because it substitutes a lay jury's decision for the expert
judgment of the FDA.79 The Court, again speaking through Justice Stevens
with a six-to-three majority, found that the FDA's product labeling approv-
als did not impliedly preempt Levine's tort claims under either impossibil-
ity or obstacle implied preemption. The Court re-affirmed the "two
cornerstones of our pre-emption jurisprudence" 8I first, that the purpose of
Congress is the "'ultimate touchstone in every pre-emption case"' and,
second, "in all pre-emption cases," 83 but particularly those involving fields
which the states have traditionally occupied, the analysis begins with the
presumption against preemption. The Court rejected Wyeth's argument
that the presumption should not apply in implied preemption cases, stating,
73. See Davis, The Battle Over Implied Preemption, supra note 6, at 1090 (chronicling
the history of the change in FDA preemption policy). The Preamble is found in Require-
ments on Content and Format of Labeling for Human Prescription Drug and Biological
Products, 71 Fed. Reg., 3922, 3934 (Jan. 24, 2006). See also Catherine M. Sharkey,
Preemption by Preamble: Federal Agencies and the Federalization of Tort Law, 56 DEPAUL
L. REv. 227 (2007).
74. See, e.g., Colacicco v. Apotex, Inc., 521 F.3d 253 (3d Cir. 2008), vacated by
Colacicco v. Apotex, Inc., 129 S. Ct. 1578 (U.S. 2009); Tucker v. SmithKline Beecham, 596
F. Supp. 2d 1225 (S.D. Ind. 2008); Knipe v. SmithKline Beecham, 583 F.Supp.2d 553 (E.D.
Pa. 2008).
75. Levine, 129 S.Ct. at 1191.
76. Id. at 1191-92.
77. Id. at 1193.
78. Levine v. Wyeth, 944 A.2d 179 (Vt. 2007).
79. Wyeth v. Levine, 129 S. Ct. at 1193-94.
80. Id. at 1190-91.
81. Id. at 1194.
82. Id. (quoting Medtronic, Inc. v. Lohr, 518 U.S. 470,485 (1996)).
83. Id. (quoting Medtronic, Inc. v. Lohr, 518 U.S. 470, 485 (1996)).
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"this Court has long held to the contrary." 84
The Court emphasized that "through many amendments to the FDCA
and to FDA regulations, it has remained a central premise of federal drug
regulation that the manufacturer bears responsibility for the content of its
label at all times."85 The Court required "clear evidence" before an impos-
sible conflict is established. There was no evidence that the FDA gave
more than "passing attention" to the issue and certainl no affirmative deci-
sion to prohibit Wyeth from strengthening its warning.
The Court's discussion of implied obstacle conflict preemption princi-
ples is important because of the contrast with the discussion in Geier. Im-
plied obstacle preemption, according to the Levine Court, requires two
things: (1) an identification of the congressional purposes or objectives
which support the federal law and, (2) a rigorous assessment of whether
Congress considered state law claims to pose an obstacle to the accom-
plishment of those objectives, not just the agency charged with effectuating
Congress' intent. Borrowing from the successful obstacle conflict preemp-
tion analysis in Geier, Wyeth had argued that Levine's tort claims were
preempted because "they interfere with 'Congress's purpose to entrust an
expert agency to make drug labeling decisions that strike a balance between
competing objectives.' 88
The Court rejected these arguments because they relied on an "unten-
able interpretation of congressional intent and an overbroad view of an
agency's power to pre-empt state law."8 9 Relying on an argument that had
been successful in Geier, Wyeth contended that once the FDA approves a
drug's label, that decision reflects both a floor and a ceiling for regulation
and state law may not hold that decision inadequate.90 The Court summari-
ly rejected this assessment of federal objectives because it was contrary to
all evidence of Congress's purposes.91 The Court explored the history of
federal regulation of pharmaceutical approvals and was influenced by Con-
gress's failure to expressly preempt, stating, "If Congress thought state-law
suits posed an obstacle to its objectives, it surely would have enacted an
express pre-emption provision at some point during the FDCA's 70-year
history." The Court found congressional silence, in the face of "aware-
ness" of concurrent state tort litigation, to be "powerful evidence that Con-
gress did not intend FDA oversight to be the exclusive means of ensuring
84. Id. at 1195, n.3.
85. Id. at 1197-98.
86. Id. at 1198.
87. Id. at 1198-99.




92. Id. at 1200. Congress had not expressly preempted state tort law claims as it had
in other contexts, such as in the MDAs. Id.
305
INDIANA HEALTH LAW REVIEW
drug safety and effectiveness." 93 The Court explored the many ways that
tort law acts as a complement to federal drug regulation,94 and found the
FDA's "newfound opinion" to the contrary to be inconsistent with the
"longstanding coexistence of state and federal law and the FDA's tradition-
al recognition of state-law remedies" 95 and, thus, unpersuasive on assessing
a current conflict with federal objectives.
Wyeth v. Levine represents a narrower implied obstacle conflict
preemption analysis than Geier. The Court seems to have settled into a
more balanced approach to the value of state common law tort actions with-
in its implied conflict preemption analysis if not so clearly in its express
preemption analysis.
IV. SYNTHESIS OF PREEMPTION ANALYSIS
The Court has at times stated that the presumption against preemption
of historic state police powers continues to operate in cases of both express
and implied preemption. The Court has also evaluated express preemption
provisions without reference to the presumption, as in Riegel. In Cipollone,
Lohr, Bates, and Altria Group, the Court required clear and manifest intent
of Congress to the contrary to defeat the presumption. The presumption
was also important in Wyeth v. Levine. The question remaining is whether
the presumption will, indeed, operate as a default in express preemption
cases where the statutory language of preemption does not lend itself to a
finding of clear congressional intent. Bruesewitz provides an answer to that
question though it is unclear what the extent of Bruesewitz's reach will be.
When an express preemption provision provides "clear and manifest"
evidence of Congress's intent, it will control.96 Justice Stevens, in Cipol-
lone, Lohr, Bates, Altria Group, and, to a lesser extent, in his concurrence
in Riegel, provides the best statement of the current manner of interpreting
express preemption provisions to discern congressional intent: narrowly
based on the ordinary meaning of the statute's terms, its structure, purposes,
and history, with an understanding that Congress would not defeat the oper-
ation of traditional, historic police powers of the states without explicitly
93. Id. Further, "[Congress] may also have recognized that state-law remedies further
consumer protection by motivating manufacturers to produce safe and effective drugs and to
give adequate warnings." Id. at 1199-1200 (alteration in original). The Court rejected reli-
ance on the FDA's "mere assertion" that state law poses an obstacle. Id. at 1201. Instead, it
confirmed that "[t]he weight we accord the agency's explanation of state law's impact on the
federal scheme depends on its thoroughness, consistency, and persuasiveness." Id.
94. Id. at 1202. "State tort suits uncover unknown drug hazards and provide incen-
tives for drug manufacturers to disclose safety risks promptly. They also serve a distinct
compensatory function that may motivate injured persons to come forward with information.
Failure-to-warn actions, in particular, lend force to the FDCA's premise that manufacturers,
not the FDA, bear primary responsibility for their drug labeling at all times." Id.
95. Id. at 1203.
96. See Davis, The "New" Presumption, supra note 3, at 1247.
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saying So.97 All of this seems to suggest that a "new" presumption against
preemption operates as a meaningful default rule when interpreting con-
gressional intent to preempt.98 Clarity is in the eyes of the beholder, as the
different results in Riegel and Altria Group suggest. Even though the Court
did not mention the presumption in Riegel, the discussion in Altria Group
on the heels of Riegel might portend that a majority has rejected a lesser
role for the presumption in express preemption cases.
"The Court seems intent on assessing statutory language with particu-
larity, to discern whether the terms used, such as "requirements," "state-
ments," or "standards," fairly include state common law claims under the
relevant statute's history alone, and not with reference to use of the terms in
other statutory schemes."99 This text-centered focus has arisen after years
of attempting to force terms from one statute, such as "requirements," to
apply to the meaning of the same term in a different statute."oo The pre-
sumption against preemption as default may reduce the overreaching of
statutory definitions by requiring a tighter fit between context and lan-
guage.10
V. VACCINE ACT PREEMPTION: BRUESEWITZ V. WYETHLLC
If the Court's analysis of express preemption provisions teaches any-
thing, it is that statutes are unique, and so is the search for congressional
intent based on statutory text. Relying on the interpretation of terms from
one statute runs the risk of proving too much in the interpretation of similar
language in another statute. In an earlier article, I proposed that recent
Vaccine Act cases, including Bruesewitz, would put this analysis to the
test.102 The Court has now answered the question by finding preemption in
a hyper-textual analysis which does not refer to the presumption against
preemption, or to other elements of preemption doctrine for that matter.
There is no question that vaccination of children has been spectacular-
ly successful in eradicating the disastrous consequences of many childhood
illnesses. There is also no question that vaccinating a child introduces a
toxin into the child's system that may cause a devastating side effect.
Those side effects are inevitable in some portion of the vaccinated popula-
tion. The Vaccine Act was intended to compensate, under a no-fault re-
gime, children who were injured from a vaccination, and the only question
97. See Davis, The "New" Presumption, supra note 3, at 1247.
98. Id.
99. Id. at 1248.
100. Id. at 1247.
101. Id.
102. See generally id.
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is which state tort laws survived the creation of the compensation scheme
and which ones did not. 03
Tort laws historically have been seen as a complement to federal drug
regulation by courts and federal regulators.""' Tort actions uncover un-
known hazards and provide incentives for drug manufacturers to disclose
safety risks promptly. They also serve a distinct compensatory function
that may motivate injured persons to come forward with and uncover in-
formation about previously undisclosed or under-disclosed risks. The
FDCA's "central premise" is that manufacturers bear primary responsibility
for their drug labeling at all times. 05 The same is true of vaccine manufac-
turers who are regulated under the Public Health Service Act,10 6 the
FDCA,107 and the Vaccine Act. os
Vaccine licenses are granted if vaccine manufacturers meet standards
designed "to insure the continued safety, purity, and potency" of vac-
cines.' 09 Since 1972, the FDA has regulated vaccines and other biologics
under the New Drug Application process."o To obtain approval, the manu-
facturer need not establish that the vaccine is the safest possible, nor that
there are no feasible alternative formulations."'1 Rather, the FDA is not
involved in initiating or conceptualizing the structure of a vaccine. The
FDA is not a drug or vaccine design agency: it is an approval agency. It has
limited authority to require post-marketing monitoring which is "not a top
priority."ll 2 The FDA relies on the Vaccine Adverse Event Reporting Sys-
tem ("VAERS"), a passive reporting system that relies on voluntary report-
ing of adverse events that are inevitably underreported." 3 Nor does it have
authority to require a manufacturer to adopt a safer alternative for a licensed
103. See generally National Childhood Vaccine Injury Act of 1986, 42 U.S.C. §§
300aa-1 to 300aa-33 (2006).
104. Wyeth v. Levine, 129 S. Ct 1187, 1202 (2009).
105. Id. at 1197-98.
106. See generally Public Health Service Act of 1944, ch. 373, 58 Stat. 682 (codified as
amended, beginning at 42 U.S.C. § 201).
107. See generally 21 U.S.C. §352.
108. See generally 42 U.S.C. §§ 300aa-1 to 300aa-34.
109. See 21 C.F.R. § 600.3(n) (2011).
110. See 21 C.F.R. § 312.2(a), 312.20-312.38. Like the proponent of a new drug, the
sponsor of a vaccine must prove, among other things, that the vaccine is safe and effective.
See 42 U.S.C. § 262 (2006).
111. See Hurley v. Lederle Labs, Inc. 863 F.2d 1173, 1177 (5th Cir. 1988) (noting that
the FDA is a "passive agency"). See also Thuy D. Pham & Annette Martinez, The Polio
Vaccine and the Restatement (Third) of Torts: Why the Controversies, 11 DEPAUL J. HEALTH
CARE L. 125, 158-59 (2008).
112. See Brief for Petitioners at 11, Bruesewitz v. Wyeth LLC, 131 S.Ct. 1068 (2011)
(No. 09-152) (quoting OFFICE OF INSPECTOR GEN., U.S. DEP'T OF HEALTH AND HUMAN
SERVICES., FDA's MONITORING OF POSTMARKETING STUDY COMMITMENTS ii-iii (June
2006)), available at 2010 WL 2130598.
113. Final Order on Categorization of Anthrax Vaccine Absorbed, 70 Fed. Reg. 75,180,
75,190 (Dec. 19, 2005).
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vaccine.1 4 The Vaccine Act creates a no-fault compensation system for
victims of certain vaccine-related injuries while encouragin vaccine manu-
facturers to continue vaccine production at reasonable cost.
None of the statutes which have been the subject of express preemp-
tion analysis have involved a congressionally mandated compensation
scheme that supplements, or displaces, state tort actions. When Congress
created the Vaccine Act administrative compensation scheme, specifically
designed to further the compensation of injured victims of vaccinations, did
Congress essentially take over the world of vaccine injury compensation?
The Supreme Court says it did."'6
The Vaccine Act preemption provision is found in a section titled
"Standards of Responsibility." That provision states: "Except as provided
in subsections (b), (c), and (e) . . . state law shall apply to a civil action
brought for damages for a vaccine-related injury or death.""' Subsection
(b)(1) states:
No vaccine manufacturer shall be liable in a civil ac-
tion for damages arising from a vaccine-related injury
or death associated with the administration of a vac-
cine after October 1, 1988, if the injury or death re-
sulted from side effects that were unavoidable even
though the vaccine was properly prepared and was
accompanied by proper directions and warnings." 8
Subsection (e), titled "Preemption" prohibits states from foreclosing any
other civil actions against manufacturers if they are not already barred by
this part."9
Hannah Bruesewitz suffered seizures in 1992 almost immediately up-
on taking the third dose of a five-dose regimen of the DTP (diphtheria, teta-
nus and pertussis) vaccine Tri-Immunol, a whole cell pertussis vaccine.12 0
The whole-cell pertussis vaccine had been linked to a variety of adverse
events which led to efforts to produce an acellular vaccine. 12 1 The acellular
vaccine was not available for Hannah's third dose in 1992, but it became
available shortly thereafter.122 Wyeth, the successor to Lederle Labs which
114. See 21. C.F.R. 601.5.
115. See id. See also Bruesewitz v. Wyeth, Inc., 561 F.3d 233, 235-36 (3d Cir. 2009)
(discussing history and structure of Act).
116. Bruesewitz v. Wyeth LLC, 131 S. Ct. 1068, 1082 (2011).
117. 42 U.S.C. § 300aa-22 (2006).
118. 42 U.S.C. § 300aa-22(b)(1).
119. 42 U.S.C. § 300aa-22(e).
120. Bruesewitz v. Wyeth, Inc., 561 F.3d 233, 236 (3d Cir. 2009). Hannah's particular
vaccine came from a lot that generated sixty-five reports of adverse reactions. Id. at 237.
121. Id. at 236.
122. Id. at 237.
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made Hannah's vaccine, voluntarily discontinued making the whole-cell
pertussis vaccine in 1998.123 Hannah's parents sought compensation from
the Vaccine Court in April 1995 for Hannah's injuries which, until one
month before, had been Table Injuries, signifying that they were compensa-
ble in Vaccine Court upon a showing of injury and proximity of onset of
injury to the administration of the vaccine.124  Hannah's parents' claims
were denied seven years later in 2002.125 Hannah's parents rejected the
court's judgment and filed suit in state court, however, the case was re-
moved to federal court, which dismissed the claim as preempted.126 The
Third Circuit Court of Appeals affirmed.127
In an earlier article, I opined that the Court should find that the statute
did not preempt all design defect litigation.12 8 The statute appears on its
face to carve out some design defect claims that are not preempted by using
the term "unavoidable." The statute is complex and its structure and history
seem to admit of different conclusions regarding preemptive intent. The
case presents a unique federal compensation scheme, however, which clear-
ly displaces the operation of a substantial amount of state common law by
its very terms.
The Supreme Court, in an opinion by Justice Scalia, finds preemption
based entirely on an analysis of the text.129 After explaining the impetus for




126. See Bruesewitz v. Wyeth, Inc., 508 F. Supp. 2d 430 (E.D. Pa. 2007).
127. Bruesewitz, 561 F.3d at 255-56. The Supreme Court granted certiorari, arguably
as a result of the split that had occurred between the federal courts of appeals and the state
courts. The Georgia Supreme Court previously upheld a finding of no preemption in a case
involving alleged neurological damages caused by vaccines made with a mercury-laden
preservative for which an alternative was available. See American Home Products Corp. v.
Ferrari, 668 S.E.2d 236 (Ga. 2008). The Georgia Supreme Court affirmed a finding of no
express preemption of the design defect claim, concluding that the statute required a case-by-
case determination of unavoidability. Id. at 238-43. Interestingly, a Pennsylvania Superior
Court has recently decided that the Vaccine Act preemption provision does not preempt such
design defect claims. See Wright v. Aventis Pasteur, Inc., 14 A.3d 850 (Pa. Super. Ct.
2011). That case was, of course, before the Supreme Court's decision in Bruesewitz.
128. Davis, The "New" Presumption, supra note 3, at 1251 ("Ferrari may have the
better analysis because it recognizes that the compensation scheme Congress created did not
specifically articulate those claims that may be deemed unavoidable. . . . The presumption
against preemption, requiring a narrow reading of the terms of a statute with a view to main-
tain state law absent clear evidence to the contrary, supports, in principle, the result in Ferra-
ri-not all design defects in vaccines are the result of unavoidable conditions. Proof of
Congress's intent will also, of course, be assessed by reference to the legislative history and
the purposes behind the compensation scheme. If clear preemptive intent can be derived, it
will control."). I also predicted in my first article on preemption, Unmasking the Presump-
tion in Favor ofPreemption, 53 S.C. L. Rev. 967 (2002), that the Supreme Court would find
express preemption in Sprietsma v. Mercury Marine, 537 U.S. 51 (2002). The Court unani-
mously found no preemption. I have learned my lesson.
129. Bruesewitz v. Wyeth LLC, 131 S. Ct. 1068, 1075-79 (2011).
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opinion strikes through the express preemption provision with the editing
pen of an expert grammarian.130 In the best sentence diagramming tradi-
tion, Justice Scalia finds that the "even though" clause clarifies the word
"unavoidable" that precedes it: "It delineates the preventative measures that
a vaccine manufacturer must have taken for a side-effect to be considered
'unavoidable' under the statute." '3 The Court concludes that, "A side ef-
fect of a vaccine could always have been avoidable by use of a differently
designed vaccine not containing the harmful element. The language of the
provision thus suggests that the design of the vaccine is a given, not subject
to question in the tort action." 32 Thus, Justice Scalia resolves the ambigui-
ty about unavoidability by concluding that it is unavoidable "with respect to
the particular design" and not with respect to competing alternative designs
that might be available.133
In design defect claims, the plaintiff must establish the condition that
makes the design defective, and that typically includes establishing an al-
ternative design that would have reduced the risk without impairing the
functioning of the product. Consequently, it is also plausible that Congress
intended that only vaccine formulations for which there was no feasible
substitute, and for which there were, therefore, unavoidable side effects,
were protected from liability. This is the dissent's argument, and one based
on comment k to Restatement (Second) of Torts section 402A, from which
Congress constructed the Vaccine Act preemption provision. 3 4 That inter-
pretation of section 22(b) also is a fair, but narrow interpretation which
gives meaning to the presumption against preemption of state law, which
Justice Scalia never mentions.
Justice Scalia supports his interpretation of the Act by noting that the
statute mentions manufacturing defect claims and failure to warn claims but
never mentions design defect claims.' 35 He concludes that this failure must
be a "deliberate choice, not inadvertence."1 3 6 "Expressio unius, exclusio
alterius."3 Justice Scalia recognizes that the "if' clause makes sense un-
130. Id. at 1073-74.
131. Id. at 1075.
132. Id.
133. Id. at 1076. See also id. at n. 35 (the Court recognizes the problem when it re-
sponds to the dissent's argument on the point in Footnote 35 by stating, "[t]he dissent makes
no effort to ground that position in the text of [the Act]. We doubt that Congress would
introduce such an amorphous test by implication when it otherwise micromanages vaccine
manufacturers." (alteration in original)).
134. Id. at 1089-1093 (Sotomayor, J., dissenting). See generally, Brief for Petitioners at
29, Bruesewitz v. Wyeth LLC, 131 S. Ct. 1068 (2011) (No. 09-152); Brief of Mark A. Geist-
feld, as Amicus Curiae in Support of Petitioners, Bruesewitz v. Wyeth LLC, 131 S. Ct. 1068
(2011) (No. 09-152).
135. Bruesewitz, 131 S. Ct. at 1078-79.
136. Id. at 1076.
137. Id.
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der either the majority's or the dissent's assessment of it.' He rejects ref-
erence to comment k as unnecessary: "'Unavoidable' is hardly a rarely
used word."039
Justice Scalia and Justice Sotomayor in dissent argue over whether the
"even though" clause is a concessive subordinate clause or whether it is a
coordinating conjunction.140 Justice Scalia agrees that Congress could have
written the clause more clearly, rendering the words after "unavoidable"
superfluous. 41 He concludes that such superfluity is not a problem because
the dissent's position "has superfluity problems of its own."1 4 2 The gram-
mar debate is resolved in Justice Scalia's favor by the six person majority.
The majority opinion also looks to the structure of the Vaccine Act to
reinforce his reading of the preemption provision.14 3 In this section of the
opinion, he discusses the difficulty of "[s]triking the right balance between
safety and efficacy" in the case of vaccines.144 He comments that the Act,
"which in every other respect micromanages manufacturers, is silent on
how to evaluate competing designs." 4 5 He expresses concern over the lack
of guidance in the Act regarding how to assess alternative designs, and con-
cludes that such lack of guidance "strongly suggests that design defects
were not mentioned because they are not a basis for liability." 46 Of course,
the FDA does not evaluate competing designs, in the vaccine context or in
the drug context. Consequently, such "lack of guidance" just as likely sup-
ports the conclusion that design defects are, indeed, intended to support a
basis for liability. The regulatory structure at the time of the Vaccine Act
defaulted to state tort law to make such assessments, as Justice Sotomayor
points out.147
The key to Justice Scalia's opinion, seems to be, his perception that
the Compensation Program, in combination with the reporting, monitoring
and collaborative work of federal regulators, was a conscious choice by
138. Id.
139. Id. at 1077.
140. Id. at 1077-78; id. at 1087 (Sotomayor, J., dissenting).
141. Id. at 1078.
142. Id. at 1078, n.48.
143. Id. at 1078-80.
144. Id. at 1079.
145. Id.
146. Id. ("Jurors, of course, often decide similar questions with little guidance, and we
do not suggest that the absence of guidance alone suggests preemption.").
147. Id. at 1097 (Sotomayor, J., dissenting) ("Although the Vaccine Act charges the
Secretary of Health and Human Services with the obligation to 'promote the development of
childhood vaccines' and 'make or assure improvements in . . . vaccines, and research on
vaccines,' neither the Act nor any other provision of federal law places a legal duty on vac-
cine manufacturers to improve the design of their vaccines to account for scientific and tech-
nological advances. Indeed, the FDA does not condition approval of a vaccine on it being
the most optimally designed among reasonably available alternatives, nor does it (or any
federal entity) ensure that licensed vaccines keep pace with technological and scientific ad-
vances." (internal citation omitted)).
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Congress "to set priorities for federal vaccine research, and to coordinate
federal vaccine safety and efficacy testing." 48 The ostensible silence re-
garding design defect litigation "reflects a sensible choice to leave complex
epidemiological judgments about vaccine design to the FDA and the Na-
tional Vaccine Program rather than juries." 4 9 The Vaccine Act's structural
quid quo pro, the fund for compensation, was at least in part in exchange
for freedom from the costly tort litigation system.150 In response to Justice
Sotomayor's concern that the FDA and the Vaccine Program are insuffi-
cient to spur adequate vaccine innovation and uncover information of risk,
Justice Scalia considers this issue to be beside the point.' 5' Not unsurpris-
ingly, Justice Scalia finds no need to refer to the legislative history even
though he recognizes that some of his colleagues would do so as a tool of
statutory interpretation.152
What is to be made then, of the importance of Bruesewitz to express
preemption analysis? It is a classic textual interpretation. Justice Scalia is
not a fan of the "fair but narrow" interpretation of such provisions, as evi-
denced by his debates with Justice Stevens in cases like Cipollone and Al-
tria Group. Bruesewitz is very much like Riegel in its approach to
assessing congressional intent solely through the text of an express preemp-
tion provision.153
Justice Scalia is also not a fan of the presumption against preemption,
which Justice Sotomayor refers to only in a footnote.154 The presumption
against preemption, had it been considered, supports the status quo of de-
sign defect liability whose operation was both known to Congress, under-
stood by Congress, and the industry, based on longstanding practices. The
Court continues to be erratic regarding the place of the presumption, signal-
ing a return to its disfavor.
Congress created a compensation alternative for most vaccine injury
claims but clearly not for all. That Congress was able to accomplish en-
actment of such a scheme seems remarkable in light of the seemingly in-
tractable legislative debates over most issues that come before Congress
that we are witness to today. One could say, with regard to the compensa-




152. Id. Justice Breyer, concurring, would look to the legislative history for support of
the interpretation of the express preemption provision which he says is "a close" question.
Id. at 1082-83 (Breyer, J., concurring).
153. See 552 U.S. 312 (2008).
154. Bruesewitz, 131 S. Ct. at 1096, n.15 (2011) (Sotomayor, J., dissenting) ("Given the
long history of state regulation of vaccines, the presumption provides an additional reason
not to read § 22(b)(1) as pre-empting all design defect claims, especially given Congress'
inclusion of an express saving clause in the same statutory section, and its use of the condi-
tional 'if' clause in defining the pre-emptive scope of the provision." (internal citations omit-
ted)).
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tion scheme, that if Congress had wanted to create a different kind of
scheme, say a truly exclusive compensation scheme, it could have said so
much more clearly than it did. That criticism proves too much because it
will, in hindsight, always be true of any legislative enactment. Tort litiga-
tion operating as a background to the Vaccine Act administrative scheme
supports both the compensatory purpose of the Act and the incentive to cre-
ate safer vaccines, but not as neatly as in cases in which there is no congres-
sionally created compromise compensation scheme. The majority
concluded that Congress need not create a compensation system that mir-
rors the tort litigation system to have intended to preempt that system.155
That is fair. It also strikes me that Bruesewitz is unlikely to have broad im-
pact on preemption of common law tort claims given the unique nature of
the congressional compensation scheme in issue.
VI. THE ROLE OF UNCERTAINTY
Vaccines have side effects, many of which are known, but not all. In-
formation about the true nature of what such toxins do once introduced into
the body, like what drugs do to the body, is produced over time-decades
perhaps. Information about the risks known when a vaccine or other drug is
approved immediately becomes out of date as soon as that vaccine or drug
is widely used in the general population. The larger the population exposed
to a drug or vaccine, the greater the potential of unanticipated side effects
and the greater the need to acquire and respond to that knowledge to en-
hance public safety. I have always advocated that the tort litigation system
provides the incentive for drug manufacturers to acquire and act on that
knowledge of which only they are fully aware. The FDA, nor any regulato-
ry agency, is simply incapable of acquiring and acting on that information
as effectively as the manufacturer. Many have commented on the FDA's
inability to track post-marketing adverse events of pharmaceuticals it ap-
proves.156 The manufacturer is in command of that information.
"Science aims at the truth without ever being certain.,' 5 The truth is
illusory. The Vaccine Program that Congress created to respond to the
known risks of childhood vaccines in 1986 was laudable. But time passes,
and additional risks become realized. Who has the incentive to make the
population aware of those risks? The well-intentioned federal regulators
155. Id. at 1079-82.
156. Id. at 1099, n.20 (Sotomayor, J., dissenting) ("[W]e observed in Levine that the
FDA is perpetually understaffed and underfunded, and the agency has been criticized in the
past for its slow response in failing to withdraw or warn about potentially dangerous prod-
ucts. These practical shortcomings reinforce the conclusion that 'state law offers an addi-
tional, and important, layer of consumer protection that complements FDA regulation."'
(internal citations omitted)).
157. DICTIONARY OF THE HISTORY OF IDEAS: CERTAINTY SINCE THE TWENTIETH
CENTURY, 323 (Philip Wiener ed., 1973).
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certainly do. But do they have the capacity? As with other drug regulation,
the FDA has limited post-marketing authority regarding vaccines. The
Centers for Disease Control gathers and tracks vaccine injury information
and does comparative analyses of those already on the market, but it does
not examine whether a safer alternative is available, and neither does any
federal government agency."ss As with research on the safety and effec-
tiveness of other drugs, research on vaccine safety remains flawed and in-
complete. The Vaccine Program provides for additional vaccines to be
added to the Table and for injuries to be included. That has not worked as
smoothly as some would have hoped.'5 9 Indeed, there is much criticism of
the way Vaccine Court operates. 1o
The Vaccine Injury Compensation Program is a good model because it
incorporates the opportunity to add vaccines and injuries to the Vaccine
Table over time. Unfortunately, more injuries have been removed from the
Table than have been added to it in the past decades,' 6 1 and vaccines have
been added with no corresponding injury side effect identified. That in it-
self may be the result of inadequate information. There continues to be a
need to maximize avenues for acquiring information about vaccine risks.
The ever present possibility of the operation of the tort system as a watch-
dog fulfills that role, but the tort system does not fit cleanly into the pro-
cess, and is often an inefficient solution. Often, the system is used as a
sledge hammer instead of the proverbial scalpel, but many safeguards of
that system have been in place for decades; the burden of proof, the re-
quirement of general and special causation, the expense of discovery and
cost of litigation to all the parties to name a few. These are significant de-
terrents to widespread overuse of the civil action instead of the administra-
tive scheme that Congress put in place.
It is such cases in which the presumption against preemption should
operate to preserve longstanding traditional tort laws of responsibility.
Product manufacturers, including vaccine manufacturers, have regulatory
and market incentives to improve their products performance, but the ever-
present possibility of the tort system operating to uncover the risks of which
only the manufacturer realistically will be aware is a powerful one. Yes,
158. Bruesewitz, 131 S. Ct. at 1099, n.19 (Sotomayor, J., dissenting).
159. See Brief of Amici Curiae National Vaccine Information Center, Its Co-Founders
and 24 Other Organizations in Support of Petitioners at 13-14, Bruesewitz v. Wyeth LLC,
131 S. Ct. 1068 (2011) (No. 09-152); Brief of Amicus Curiae Marguerite Willner in Support
of Petitioners at 21-23, Bruesewitz v. Wyeth LLC, 131 S. Ct. 1068 (2011) (No. 09-152).
160. See National Vaccine Injury Compensation Program, HRSA.Gov,
http://www.hrsa.gov/vaccinecompensation/statistics-report.htm#claims'filed (last visited
May 19, 2011) (showing approximately twenty percent of petitions that have been compen-
sated).
161. See, e.g., Brief of Vaccine Injured Petitioners Bar Association, the George Wash-
ington University Law School Vaccine Injury Clinic, and Zenoria Phillips Deloatch, as Per-
sonal Representative of the Estate of Moshella F. Roberts, as Amici Curiae in Support of
Petitioners passim, Bruesewitz v. Wyeth LLC, 131 S. Ct. 1068 (2011) (No. 09-152).
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the need for a healthy vaccine supply is great. The burden to establish con-
gressional intent to immunize the entire industry for its design choices
should also be great and the presumption against preemption represents that
burden. The majority in Bruesewitz did not see it that way.
The Court may be determined to simply resolve preemption matters
on a statute by statute basis, which will have the effect of creating adminis-
trative agency preemption for some agencies and for some tort claims but
not for others. That result would be unfortunate and unfair. It would in-
crease the uncertainty that currently exists about the preemptive scope of
regulatory schemes. It would attach a preemption analysis to statutory lan-
guage that the authoring Congresses could not have imagined.
It may be, however, that the agency-by-agency approach the Supreme
Court is implementing through its preemption doctrine will have the effect
of spurring society to have the kind of society wide conversation that Judge
Calabresi envisions.162 It may force our legislators, regulators, judges, law-
yers and policy experts to engage in a meaningful way about the kind of
regulatory system that may be needed to respond to excessive risks in our
increasingly complex society, to compensate fairly for those risks, and to
reduce them appropriately in the balanced way that the majority opinion in
Bruesewitz thought Congress did in the case of vaccines.
Uncertainty is inevitable. Systems must respond to inevitable uncer-
tainty and inadequacy of information. Having a mechanism by which the
uncertainty inherent in one system is evaluated through the lens of another,
even if only occasionally, enhances the opportunity to reduce the uncertain-
ty. We should not so quickly dismiss the tort litigation system as an im-
portant, longstanding complement to more formal regulatory action for
responding to uncertainty in risk information.
In the light of the past twenty years, the Vaccine Program has been
moderately successful. Moderately, because there are many who complain
the Program is slow, unfriendly to victims, and more restrictive in operation
than was originally intended. 16  The operation of the Program was not at
issue in Bruesewitz. One might hope that, now that design defect litigation
is no longer available as a complement to the compensation system, the
Program will increasingly come under scrutiny to defend its effectiveness in
carrying out its mandate to compensate and increase vaccine safety.
162. See Calabresi, supra note 15.
163. See Brief of Amicus Curiae Marguerite Willner, supra note 159, at 3. ("The com-
pensation system has not lived up to Congress's expectations. HHS, which administers the
Program, has wrought administrative changes that make it difficult for petitioners to recover
for their injuries. . . . These difficulties, coupled with the dearth of information about vac-
cine safety, render state tort actions a critical safety-valve in the regulatory system.").
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